New insight of pancreatic imaging: from “unexplored” to “explored”

Hiromu Mori

Department of Radiology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-City, Oita 879-5593, Japan

Abstract

Pancreatic cancer remains one of the most difficult neoplasms for early diagnosis and treatment. Recent advances of imaging including 3D volume data setting in multidetector-row CT (MDCT) and MRI are urging us to focus on the imaging of normal and pathological conditions of pancreatic parenchyme and peripancreatic structures, which are frequently involved by pancreatic cancers and are affecting the prognosis of patients with pancreatic cancers. In this Feature Section, five main topics of pancreatic imaging are addressed: pancreatic arterial territories, imaging of the intra- and peripancreatic venous anatomy and its clinical significance, imaging of the peripancreatic lymphatic network and its clinical significance for staging of pancreatic cancer, perfusion characteristics of pancreatic cancer to differentiate chronic mass-forming pancreatitis, and development of IPMNs (Intraductal papillary mucinous neoplasms of the pancreas) to adenocarcinoma and pancreatic invasion. The content is outlined here with some supplements.

Correspondence to: Hiromu Mori; email: morihrmu@med.oita-u.ac.jp

© The Author(s) 2008. This article is published with open access at Springerlink.com
Abdom Imaging (2010) 35:130–133
DOI: 10.1007/s00261-008-9471-x

Pancreatic cancer remains one of the most difficult neoplasms for early diagnosis and treatment. During the past few decades, the incidence of pancreatic carcinomas has increased all over the world, and these tumors have become the 4th or 5th most common cause of death from cancer. Only 10%–30% of patients with pancreatic carcinoma have resectable disease at diagnosis. Therefore, long-term survival is extremely rare. Many researchers have been making every effort to find a way for early diagnosis, accurate staging, and effective treatment of pancreatic cancers. However, it was recently reported that use of the brand-new molecular-targeted drug with gemcitabine for systemic chemotherapy of patients with advanced pancreatic cancers could extend median survival by only one month [1]. So, when considering the strategy of diagnosis and treatment of pancreatic cancer, the following questions arise: How and what do we know about the anatomy of the pancreas? Do we miss something very basic?

The term pancreas is derived from Greek and means literally “an organ colored like beef or meat.” The Chinese character representing pancreas in Japanese means “an organ which consists of glands.” On the other hand, the original Chinese character representing pancreas means “an organ of remote region or unexplored territory” (Fig. 1). It is indeed true that the pancreas is still an unexplored organ, compared to the liver whose arterial, portal venous, hepatic venous, and segmental anatomy had been well established many years ago [2]. Little attention has been paid to the arterial territory of the pancreas, the anatomy of intra- and peripancreatic veins, and the anatomy of peripancreatic lymphatic networks.

In this Feature Section, five main topics of pancreatic imaging are addressed: pancreatic arterial territories, imaging of the intra- and peripancreatic venous anatomy and its clinical significance, imaging of the peripancreatic lymphatic network and its clinical significance for staging of pancreatic cancer, perfusion characteristics of pancreatic cancer to differentiate chronic mass-forming pancreatitis, and development of IPMNs (Intraductal papillary mucinous neoplasms of the pancreas) to adenocarcinoma and pancreatic invasion. The content is outlined here with some supplements.

Key words: Pancreatic arterial territories—Pancreatic venous anatomy—Peripancreatic—Lymphatic network—Perfusion characteristics of pancreatic cancer—Intraductal papillary mucinous neoplasms of the pancreas
An organ consisting of “glands”

An organ of “remote region”

An organ of “unexplored territory”

Fig. 1. Pancreas as unexplored territory. Upper row: Japanese Kanji (Chinese character) representing pancreas means “an organ consisting of glands.” Lower row: Chinese character representing pancreas means “an organ of remote region” or “an organ of unexplored territory.”

Imaging anatomy of the pancreas and its clinical significance

Arterial territories or segmental anatomy of the pancreas

It is not surprising that there had been no solid concept of the arterial territories or segments of the pancreas [3], because there was little clinical need for pancreatic segmentectomy or segmental resection; also there had been little clinical success of the less-invasive targeted therapy. As shown in this Feature Section, follow-up by imaging of patients with intraductal mucinous neoplasms (IP-MNs) of the pancreas may be the most effective way to find the early-stage pancreatic cancer. Pancreatic segmentectomy has precisely been discussed for the IPMNs [4, 5]. Clinical application of the less invasive targeted therapy such as intra-arterial chemotherapy [6] or gene therapy [7–9] is in the early stages. In the near future, knowledge of the arterial territories or segmental anatomy of the pancreas will be appreciated for both surgery and locally targeted less-invasive therapy. In this Feature Section, Dr. Okahara and colleagues describe detailed anatomic variation of the venous drainage of intrapancreatic veins by analysis of the venous phase of multidetector-row CT (MDCT).

Extrapancreatic neural plexus and peripancreatic lymphatic networks

The new UICC TNM classification published in 2002 reflects the influencing prognostic factors of patients with pancreatic cancer [14]. In clinical practice, there are very few patients with stage I pancreatic cancer because there is no screening method established (nor risk-group setting) for pancreatic cancer at this point. Furthermore, it is very important to know that even T1 pancreatic cancer can infiltrate surrounding peripancreatic tissue including regional lymph nodes [15]. Despite recent advances of imaging including 3D volume data setting in multidetector-row CT (MDCT) and MRI, little attention has been paid to imaging of normal and pathological conditions of peripancreatic lymphatic networks, peripancreatic neural plexuses, and pancreatic veins, which are frequently involved by pancreatic cancers and affect the prognosis of patients with pancreatic cancers.

Retroperitoneal infiltration via extrapancreatic nerve plexuses is one of the major causes of postoperative recurrence. The second portion of the pancreatic head nerve plexus is frequently involved and is contiguous to the root of the small bowel mesentery. The normal extrapancreatic nerve plexus can hardly be seen on CT, but it is known that the inferior pancreaticoduodenal artery (IPDA) and vein (IP) pass through the second portion of the pancreatic head nerve plexus [16, 17]. Recently, evaluation by CT is reported to be able to demonstrate tumor invasion to the extrapancreatic nerve plexus showing obliteration of the IP and/or the first jejunal trunk (JT) [18].

Imaging findings of peripancreatic lymphatic invasion by pancreatic cancer have not been described before, though lymphatic networks exist around the pancreas having close anatomical relationship with neural plexuses and blood vessels. On pathologic examinations, there may be two ways of peripancreatic lymphatic invasion by
pancreatic cancer; tumor emboli that fill up the dilated lymphatics [19] and tumor extension along the lymphatic channels (Fig. 2). In this Feature Section, Dr. Sai and colleagues describe the CT features of normal peripancreatic lymphatic networks, and state that areas of increased attenuation in the peripancreatic fat plane corresponding with anatomical networks in the patients with known pancreatic cancer may indicate cancer invasion to lymphatics.

**Differentiation of pancreatic cancer from pancreatic fibrosis by perfusion characteristics on CT and MRI**

In some clinical cases, difficulties can arise in the differentiation of autoimmune pancreatitis (AIP) and mass-forming chronic pancreatitis from pancreatic cancer [20, 21]. Late enhancement of pancreatic carcinomas has been observed on CT by a few investigators [22, 23]. On delayed phased MRI, significant differences between enhancement of cancer and benign fibrosis have been reported [24]. Rich fibrotic stroma in pancreatic adenocarcinoma would play a major role in these perfusion characteristics along with architectures of so-called tumor vessels [25] and vascularity of the cancer. In this Feature Section, Dr. Hata and colleagues describe the time-attenuation curve (TAC) pattern of pancreatic cancer on triple-phase postcontrast CT with correlation to histopathologic features including amount of fibrotic stroma and vascularity. Dr. Yamada and colleagues describe TAC patterns of normal pancreatic parenchyma, chronic pancreatitis, and pancreatic cancer. Chronic pancreatitis and pancreatic adenocarcinoma could be differentiated according to TACs of the second and third phases obtained during triple-phase CT with diagnostic accuracy of around 90%.

**IPMNs as a clue for detecting early-stage pancreatic cancer**

The risk of developing pancreatic cancer for patients with hereditary pancreatitis (HP) is extremely high [26]. This poses opportunities for secondary screening in those patients. Otherwise there has been no effective screening method for detecting early-stage pancreatic cancer, though a lot of clinical efforts have been made. Periodic checkups by imaging and/or EUS (endoscopic ultrasound) for patients with main pancreatic duct dilatation or cystic lesions are considered to be an effective method for the early detection of pancreatic cancer [27]. The possibility of clinical utility of genomic abnormalities including tumor suppressor genes such as Ki-67, p53, and DPC4 remains unclear. Stool K-ras analysis has been reported as a potential screening method for the early detection of pancreatic adenocarcinoma and precursor lesions such as pancreatic ductal mucinous cell hyperplasia [28]. Identifying the responsible gene abnormalities for early pancreatic cancer using array-based comparative genomic hybridization is just in the early stages.

Intraductal papillary mucinous neoplasm (IPMN) is a relatively new entity and has been increasingly recognized recently as belonging to a well-characterized group of intraductal mucin-producing neoplasms of the pancreas with malignant potential [29]. Thin-section dynamic CT has been shown to be a useful modality for follow-up of IPMNs, especially those that have progressed into invasive carcinomas [30, 31]. When a solid mass in the pancreatic parenchyma surrounding the dilated pancreatic ducts appears on follow-up CT, progression to an invasive carcinoma should be considered and surgical resection is recommended. In this Feature Section, Dr. Yamada and colleagues describe the
imaging features of the invasive carcinoma originating from intraductal papillary mucinous neoplasms of the pancreas.

**Conclusion**

Recognition and understanding of the imaging anatomy of the pancreas, including pancreatic veins, lymphatic pathways, and extrapancreatic neural plexuses, might lead to the accurate staging of pancreatic cancer. Knowledge of arterial territories or segmental anatomy of the pancreas might be useful for locally targeted treatments for pancreatic cancer. Understanding perfusion characteristics of pancreatic cancer, which is determined by the vascularity and presence of fibrotic stroma, can differentiate cancer from benign pancreatic fibrosis. Careful follow-up of IPMNs leads to detection of early-stage pancreatic cancers.

I sincerely hope that the knowledge communicated in this Feature Section will be shared by many clinical researchers and will underscore the next step in pancreatic imaging and treatment.

*Open Access.* This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**References**

1. Vervenne W, Bennouna J, Humblet Y, et al. (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 26(suppl; abstr 4507)
2. The Liver (2004) In: Standring S, et al. (ed) Gray's anatomy: the anatomical basis of clinical practice, 39th ed. Churchill Livingstone, pp 1213–1225
3. Sakuhara Y, Kodama Y, Abo D, et al. (2008) Evaluation of the vascular supply to regions of the pancreas on CT during arteriography. Abdom Imaging 33(5):563–570
4. Seyama Y, Sakamoto Y, Sano K, et al. (2003) Anatomical segmentectomy of the pancreas head: can this procedure be curatively applied for intraductal papillary mucinous tumors? Pancreas 27(3):270–272
5. Sakamoto Y, Nagai M, Tanaka N, et al. (2000) Anatomical segmentectomy of the head of the pancreas along the embryological fusion plane: a feasible procedure? Surgery 128(5):822–831
6. Sasada T, Denro Y, Tanaka T, et al. (2008) Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study. Am J Clin Oncol 31(1):71–78
7. Saraga G, Mafficini A, Ghaneh P, Sorio C, Costello E (2007) Both HIV- and EIAV-based lentiviral vectors mediate gene delivery to pancreatic cancer cells and human pancreatic primary patient xenografts. Cancer Gene Ther 14(9):781–790
8. Ramirez PJ, Vickers SM (2004) Current status of gene therapy for pancreatic cancer. Curr Surg 61(1):84–92
9. MacKenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5(9):541–549
10. Loyer EM, David CL, Dubrow RA, Evans DB, Charnsangavej C (1996) Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT. Abdom Imaging 21(3):207–210
11. Mori H, Miyake H, Aikawa H, et al. (1991) Dilated posterior superior pancreaticoduodenal vein: recognition with CT and clinical significance in patients with pancreatico-biliary carcinomas. Radiology 181:793–800
12. Mori H, McGrath FP, Malone DE, Stevenson GW (1992) The gastroduodenal trunk and its tributaries: CT evaluation. Radiology 182:871–877
13. Yamada Y, Mori H, Kiyosue H, et al. (2000) CT assessment of the inferior peripancreatic veins: Clinical significance. AJR 174:677–684
14. Sobin LH, Wittekind Ch (eds) (2002) TNM: classification of malignant tumours, 6th edn. International Union Against Cancer (UICC), pp 93–96
15. Nagai H, Kuroda A, Morioka Y (1986) Lymphatic and local spread of T1 and T2 pancreatic cancer. A study of autopsy material. Ann Surg 204(1):65–71
16. Kayahara M, Nagakata T, Konishi I, et al. (1991) Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 10(2):105–111
17. Nakao A, Harada A, Nonami T, Kaneko T, Takagi H (1996) Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Cancer 124(4):357–361
18. Tian H, Mori H, Matsumoto S, et al. (2007) Extrapancreatic neural plexus invasion by carcinomas of the pancreatic head region: evaluation using thin-section helical CT. Radiat Med 25(4):141–147
19. Noto M, Miwa K, Kitagawa H, et al. (2005) Pancreas head carcinoma: frequency of invasion to soft tissue adherent to the superior mesenteric artery. Am J Surg Pathol 29(8):1056–1061
20. Lee H, Lee JK, Kang SS, et al. (2007) Is there any clinical or radiologic feature as a preoperative marker for differentiating mass-forming pancreatitis from early-stage pancreatic adenocarcinoma? Hepatogastroenterology 54(79):2134–2140
21. Manfredi R, Graziani R, Cicero C, et al. (2006) Autoimmune pancreatitis: CT patterns and their changes after steroid treatment. Radiology 247(2):435–443
22. Lu DS, Vedantham S, Krasny RM, et al. (1996) Two-phase helical CT for pancreatic tumors: pancreatic versus hepatic phase enhancement of tumor, pancreas, and vascular structures. Radiology 199(3):697–701
23. Fletcher JG, Wiersma MJ, Farrell MA, et al. (2003) Pancreatic malignancy: value of arterial, pancreatic, and hepatic phase imaging with multi-detector row CT. Radiology 229(1):81–90
24. Johnson PT, Outwater EK (1999) Pancreatic carcinoma versus chronic pancreatitis: dynamic MR imaging. Radiology 212(2):213–218
25. McDonald DM, Choyke PL (2003) Imaging of angiogenesis: from microscope to clinic. Nat Med 9(6):713–725
26. Canto MI (2008) Screening and surveillance approaches in familial pancreatic cancer. Gastrointest Endosc Clin N Am 18(3):535–553
27. Canto MI (2007) Strategies for screening for pancreatic adenocarcinoma in high-risk patients. Semin Oncol 34(4):295–302
28. Berndt C, Haubold K, Wenger F, et al. (1998) K-ras mutations in stools and tissue samples from patients with malignant and non-malignant pancreatic diseases. Clin Chem 44(10):2103–2107
29. Biankin AV, Kench JG, Biankin SA, et al. (2004) Pancreatic intraepithelial neoplasia in association with intraductal papillary mucinous neoplasms of the pancreas: implications for disease progression and recurrence. Am J Surg Pathol 28(9):1184–1192
30. Yamada Y, Mori H, Matsumoto S (2008) Intraductal papillary mucinous neoplasms of the pancreas: correlation of helical CT and dynamic MR imaging features with pathologic findings. Abdom Imaging 33(4):474–4781
31. Yamada Y, Mori H, Matsumoto S, Kamei N, Hongo N (2006) Invasive carcinomas derived from intraductal papillary mucinous neoplasms of the pancreas: a long-term follow-up assessment with CT imaging. J Comput Assist Tomogr 30(6):885–890